Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yuko Katakai is active.

Publication


Featured researches published by Yuko Katakai.


Nature Genetics | 2012

Plasmodium cynomolgi genome sequences provide insight into Plasmodium vivax and the monkey malaria clade

Shin Ichiro Tachibana; Steven A. Sullivan; Satoru Kawai; Shota Nakamura; Hyunjae R. Kim; Naohisa Goto; Nobuko Arisue; Nirianne Marie Q. Palacpac; Hajime Honma; Masanori Yagi; Takahiro Tougan; Yuko Katakai; Osamu Kaneko; Toshihiro Mita; Kiyoshi Kita; Yasuhiro Yasutomi; Patrick L. Sutton; Rimma Shakhbatyan; Toshihiro Horii; Teruo Yasunaga; John W. Barnwell; Ananias A. Escalante; Jane M. Carlton; Kazuyuki Tanabe

P. cynomolgi, a malaria-causing parasite of Asian Old World monkeys, is the sister taxon of P. vivax, the most prevalent malaria-causing species in humans outside of Africa. Because P. cynomolgi shares many phenotypic, biological and genetic characteristics with P. vivax, we generated draft genome sequences for three P. cynomolgi strains and performed genomic analysis comparing them with the P. vivax genome, as well as with the genome of a third previously sequenced simian parasite, Plasmodium knowlesi. Here, we show that genomes of the monkey malaria clade can be characterized by copy-number variants (CNVs) in multigene families involved in evasion of the human immune system and invasion of host erythrocytes. We identify genome-wide SNPs, microsatellites and CNVs in the P. cynomolgi genome, providing a map of genetic variation that can be used to map parasite traits and study parasite populations. The sequencing of the P. cynomolgi genome is a critical step in developing a model system for P. vivax research and in counteracting the neglect of P. vivax.


Journal of General Virology | 2011

Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity.

Tsutomu Omatsu; Meng Ling Moi; Takanori Hirayama; Tomohiko Takasaki; Shinichiro Nakamura; Shigeru Tajima; Mikako Ito; Tomoyuki Yoshida; Akatsuki Saito; Yuko Katakai; Hirofumi Akari; Ichiro Kurane

Dengue virus (DENV) causes a wide range of illnesses in humans: dengue fever (DF), dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Animal models that constantly develop high levels of viraemia are required for the development of protective and preventive measures. Common marmosets (Callithrix jacchus) demonstrated high levels of viraemia after inoculation with clinical isolates of four serotypes of DENV; in particular, over 10(6) genome copies ml(-1) after inoculation with DENV-2. Non-structural protein 1 and DENV-specific IgM and IgG antibodies were consistently detected. The DENV-2 genome was detected in lymphoid organs including the lymph nodes, spleen and thymus, and also in non-lymphoid organs. DENV antigen was detected by immunohistochemistry in the liver and spleen from inoculated marmosets. Four marmosets were reinoculated with DENV-2 at 33 weeks after primary inoculation with DENV-2. The DENV-2 genome was not detected in any of these marmosets, indicating protection from a secondary infection. The results indicate that common marmosets are highly sensitive to DENV infection, and suggest that marmosets could be a reliable primate model for the evaluation of candidate vaccines.


Proceedings of the National Academy of Sciences of the United States of America | 2014

Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist

Kouji Kobiyama; Taiki Aoshi; Hirotaka Narita; Etsushi Kuroda; Masayuki Hayashi; Kohhei Tetsutani; Shohei Koyama; Shinichi Mochizuki; Kazuo Sakurai; Yuko Katakai; Yasuhiro Yasutomi; Shinobu Saijo; Yoichiro Iwakura; Shizuo Akira; Cevayir Coban; Ken J. Ishii

Significance CpG oligodeoxynucleotide (ODN), a Toll-like receptor 9 ligand, is a promising immunotherapeutic agent; however, developing an IFN-inducing CpG ODN forming a stable nanoparticle without aggregation has been unsuccessful. Here we generated a nanoparticulate CpG ODN (K3) wrapped by the nonagonistic Dectin-1 ligand schizophyllan (SPG), K3-SPG. K3-SPG stimulates human peripheral blood mononuclear cells to produce large amounts of both type I and II IFN. K3-SPG thus became a potent adjuvant, especially for cytotoxic T-lymphocyte (CTL) induction to coadministered protein antigens without conjugation, which is attributable to its nanoparticulate nature rather than to targeting Dectin-1. Protective potency of K3-SPG as an influenza vaccine adjuvant was demonstrated in both murine and nonhuman primate models. K3-SPG may be used as an IFN inducer as well as a CTL inducer for immunotherapeutic applications. CpG DNA, a ligand for Toll-like receptor 9 (TLR9), has been one of the most promising immunotherapeutic agents. Although there are several types of potent humanized CpG oligodeoxynucleotide (ODN), developing “all-in-one” CpG ODNs activating both B cells and plasmacytoid dendritic cells forming a stable nanoparticle without aggregation has not been successful. In this study, we generated a novel nanoparticulate K CpG ODN (K3) wrapped by the nonagonistic Dectin-1 ligand schizophyllan (SPG), K3-SPG. In sharp contrast to K3 alone, K3-SPG stimulates human peripheral blood mononuclear cells to produce a large amount of both type I and type II IFN, targeting the same endosome where IFN-inducing D CpG ODN resides without losing its K-type activity. K3-SPG thus became a potent adjuvant for induction of both humoral and cellular immune responses, particularly CTL induction, to coadministered protein antigens without conjugation. Such potent adjuvant activity of K3-SPG is attributed to its nature of being a nanoparticle rather than targeting Dectin-1 by SPG, accumulating and activating antigen-bearing macrophages and dendritic cells in the draining lymph node. K3-SPG acting as an influenza vaccine adjuvant was demonstrated in vivo in both murine and nonhuman primate models. Taken together, K3-SPG may be useful for immunotherapeutic applications that require type I and type II IFN as well as CTL induction.


Human Vaccines & Immunotherapeutics | 2013

TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models

Takahiro Tougan; Taiki Aoshi; Cevayir Coban; Yuko Katakai; Chieko Kai; Yasuhiro Yasutomi; Ken J. Ishii; Toshihiro Horii

The SE36 antigen, derived from serine repeat antigen 5 (SERA5) of Plasmodium falciparum, is a promising blood stage malaria vaccine candidate. Ongoing clinical trials suggest the efficacy of the SE36 vaccine could be increased by the incorporation of more effective adjuvants into the vaccine formulation. In this study, we assessed the safety, immunogenicity and protective efficacy of SE36/AHG formulated with TLR9 ligand adjuvants K3 CpG oligodeoxyribonucleotides (CpG ODNs) (K3 ODN), D3 ODN or synthetic hemozoin, in two non-human primate models. SE36/AHG with or without each adjuvant was administrated to cynomolgus monkeys. A combination of TLR9 ligand adjuvant with SE36/AHG induced higher humoral and cellular immune response compared with SE36/AHG alone. Administration of a crude extract of P. falciparum parasite resulted in the induction of more SE36-specific IgG antibodies in monkeys vaccinated with a combination of SE36/AHG and adjuvant, as opposed to vaccination with SE36/AHG alone. The most effective TLR9 ligand, K3 ODN, was chosen for further vaccine trials in squirrel monkeys, in combination with SE36/AHG. All monkeys immunized with the combined SE36/AHG and K3 ODN formulation effectively suppressed parasitemia and symptoms of malaria following challenge infections. Furthermore, no serious adverse events were observed. Our results show that the novel vaccine formulation of K3 ODN with SE36/AHG demonstrates safety, potent immunogenicity and efficacy in nonhuman primates, and this vaccine formulation may form the basis of a more effective malaria vaccine.


Journal of Medical Primatology | 2012

Changes in hematological and serum biochemical parameters in common marmosets (Callithrix jacchus) after inoculation with dengue virus

Tsutomu Omatsu; Meng Ling Moi; Tomohiko Takasaki; Shinichiro Nakamura; Yuko Katakai; Shigeru Tajima; Mikako Ito; Tomoyuki Yoshida; Akatsuki Saito; Hirofumi Akari; Ichiro Kurane

Background  Marmosets are susceptible to dengue virus (DENV) infection. However, blood parameter data and clinical signs of DENV‐infected marmosets are limited.


Journal of Immunology | 2015

Hydroxypropyl-β-Cyclodextrin Spikes Local Inflammation That Induces Th2 Cell and T Follicular Helper Cell Responses to the Coadministered Antigen

Motoyasu Onishi; Koji Ozasa; Kouji Kobiyama; Keiichi Ohata; Mitsutaka Kitano; Keiichi Taniguchi; Tomoyuki Homma; Masanori Kobayashi; Akihiko Sato; Yuko Katakai; Yasuhiro Yasutomi; Edward Wijaya; Yoshinobu Igarashi; Noriyuki Nakatsu; Wataru Ise; Takeshi Inoue; H. Yamada; Alexis Vandenbon; Daron M. Standley; Tomohiro Kurosaki; Cevayir Coban; Taiki Aoshi; Etsushi Kuroda; Ken J. Ishii

Cyclodextrins are commonly used as a safe excipient to enhance the solubility and bioavailability of hydrophobic pharmaceutical agents. Their efficacies and mechanisms as drug-delivery systems have been investigated for decades, but their immunological properties have not been examined. In this study, we reprofiled hydroxypropyl-β-cyclodextrin (HP-β-CD) as a vaccine adjuvant and found that it acts as a potent and unique adjuvant. HP-β-CD triggered the innate immune response at the injection site, was trapped by MARCO+ macrophages, increased Ag uptake by dendritic cells, and facilitated the generation of T follicular helper cells in the draining lymph nodes. It significantly enhanced Ag-specific Th2 and IgG Ab responses as potently as did the conventional adjuvant, aluminum salt (alum), whereas its ability to induce Ag-specific IgE was less than that of alum. At the injection site, HP-β-CD induced the temporary release of host dsDNA, a damage-associated molecular pattern. DNase-treated mice, MyD88-deficient mice, and TBK1-deficient mice showed significantly reduced Ab responses after immunization with this adjuvant. Finally, we demonstrated that HP-β-CD–adjuvanted influenza hemagglutinin split vaccine protected against a lethal challenge with a clinically isolated pandemic H1N1 influenza virus, and the adjuvant effect of HP-β-CD was demonstrated in cynomolgus macaques. Our results suggest that HP-β-CD acts as a potent MyD88- and TBK1-dependent T follicular helper cell adjuvant and is readily applicable to various vaccines.


Frontiers in Microbiology | 2011

Long-term persistent GBV-B infection and development of a chronic and progressive hepatitis C-like disease in marmosets

Yuki Iwasaki; Kenichi Mori; Koji Ishii; Noboru Maki; Sayuki Iijima; Tomoyuki Yoshida; Sachi Okabayashi; Yuko Katakai; Young-Jung Lee; Akatsuki Saito; Hiromi Fukai; Nobuyuki Kimura; Naohide Ageyama; Sayaka Yoshizaki; Tetsuro Suzuki; Yasuhiro Yasutomi; Tatsuo Miyamura; Mari Kannagi; Hirofumi Akari

It has been shown that infection of GB virus B (GBV-B), which is closely related to hepatitis C virus, develops acute self-resolving hepatitis in tamarins. In this study we sought to examine longitudinally the dynamics of viral and immunological status following GBV-B infection of marmosets and tamarins. Surprisingly, two of four marmosets but not tamarins experimentally challenged with GBV-B developed long-term chronic infection with fluctuated viremia, recurrent increase of alanine aminotransferase and plateaued titers of the antiviral antibodies, which was comparable to chronic hepatitis C in humans. Moreover, one of the chronically infected marmosets developed an acute exacerbation of chronic hepatitis as revealed by biochemical, histological, and immunopathological analyses. Of note, periodical analyses of the viral genomes in these marmosets indicated frequent and selective non-synonymous mutations, suggesting efficient evasion of the virus from antiviral immune pressure. These results demonstrated for the first time that GBV-B could induce chronic hepatitis C-like disease in marmosets and that the outcome of the viral infection and disease progression may depend on the differences between species and individuals.


Journal of General Virology | 2014

Demonstration of marmosets (Callithrix jacchus) as a non-human primate model for secondary dengue virus infection: high levels of viraemia and serotype cross-reactive antibody responses consistent with secondary infection of humans

Meng Ling Moi; Tomohiko Takasaki; Tsutomu Omatsu; Shinichiro Nakamura; Yuko Katakai; Yasushi Ami; Yuriko Suzaki; Masayuki Saijo; Hirofumi Akari; Ichiro Kurane

There are four dengue virus (DENV) serotypes. Primary infection with one does not confer protective immunity against the others. We have reported previously that the marmoset (Callithrix jacchus) is a useful primary DENV infection model. It has been reported that secondary DENV infection with a heterotypic serotype induces viraemia kinetics and antibody responses that differ from those in primary infection. Thus, it is important to determine the utility of the marmoset as a model for secondary DENV infection. Marmosets were infected with heterologous DENV by secondary inoculation, and viraemia kinetics and antibody responses were analysed. The marmosets consistently developed high levels of viraemia after the secondary inoculation with heterologous DENV serotypes. IgM responses were lower compared with primary inoculation responses, whilst IgG responses were rapid and high. Neutralizing activities, which possessed serotype cross-reactive activities, were detected as early as 4 days after inoculation. In addition, infectious viraemia titres were higher when assayed with Fcγ receptor-expressing baby hamster kidney (BHK) cells than when assayed with conventional BHK cells, suggesting the presence of infectious virus-antibody immune complexes. After secondary infection with heterotypic DENV, the marmosets demonstrated viraemia kinetics, IgM and IgG responses, and high levels of serotype cross-reactive neutralizing antibody responses, all of which were consistent with secondary DENV infection in humans. The results indicate the marmoset as a useful animal for studying secondary, as well as primary, DENV infection.


Frontiers in Microbiology | 2010

Characterization of natural killer cells in tamarins: a technical basis for studies of innate immunity.

Tomoyuki Yoshida; Akatsuki Saito; Yuki Iwasaki; Sayuki Iijima; Terue Kurosawa; Yuko Katakai; Yasuhiro Yasutomi; Keith A. Reimann; Toshiyuki Hayakawa; Hirofumi Akari

Natural killer (NK) cells are capable of regulating viral infection without major histocompatibility complex restriction. Hepatitis C is caused by chronic infection with hepatitis C virus (HCV), and impaired activity of NK cells may contribute to the control of the disease progression, although the involvement of NK cells in vivo remains to be proven. GB virus B (GBV-B), which is genetically most closely related to HCV, induces acute and chronic hepatitis upon experimental infection of tamarins. This non-human primate model seems likely to be useful for unveiling the roles of NK cells in vivo. Here we characterized the biological phenotypes of NK cells in tamarins and found that depletion of the CD16+ subset in vivo by administration of a monoclonal antibody significantly reduced the number and activity of NK cells.


Archives of Virology | 2012

CD16+ natural killer cells play a limited role against primary dengue virus infection in tamarins

Tomoyuki Yoshida; Tsutomu Omatsu; Akatsuki Saito; Yuko Katakai; Yuki Iwasaki; Sayuki Iijima; Terue Kurosawa; Masataka Hamano; Shinichiro Nakamura; Tomohiko Takasaki; Yasuhiro Yasutomi; Ichiro Kurane; Hirofumi Akari

CD16 is a major molecule expressed on NK cells. To directly assess the role of natural killer (NK) cells in dengue virus (DENV) infection in vivo, CD16 antibody-treated tamarins were inoculated with a DENV-2 strain. This resulted in the transient depletion of CD16+ NK cells, whereas no significant effects on the overall levels or kinetics of plasma viral loads and antiviral antibodies were observed in the treated monkeys when compared to control monkeys. It remains elusive whether the CD16− NK subpopulation could play an important role in the control of primary DENV infection.

Collaboration


Dive into the Yuko Katakai's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Akatsuki Saito

Primate Research Institute

View shared research outputs
Top Co-Authors

Avatar

Shinichiro Nakamura

Shiga University of Medical Science

View shared research outputs
Top Co-Authors

Avatar

Ichiro Kurane

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Tomohiko Takasaki

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Tomoyuki Yoshida

Primate Research Institute

View shared research outputs
Top Co-Authors

Avatar

Tsutomu Omatsu

Tokyo University of Agriculture and Technology

View shared research outputs
Top Co-Authors

Avatar

Naohide Ageyama

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Satoru Kawai

Dokkyo Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge